Following a request received from the company, NICE will be undertaking an appraisal of Regorafenib for previously treated metastatic colorectal cancer. This was originally terminated guidance TA334.
The appraisal is expected to start during January 2022 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an invitation to participate in the appraisal during mid-March 2022. The deadline for submissions is expected in approximately late-May 2022.